Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vintafolide + pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer
2011-000348-11Phase 3Terminated
- Sponsor
- Endocyte
- Start
- Jul 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Vintafolide + pegylated liposomal doxorubicin with Pegylated liposomal doxorubicin (2 arms). Primary endpoint: Progression-free survival. Started Jul 2011; status: terminated.
02
Drugs
vintafolidedoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2011-000348-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000348-11.